At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
PD-1 Inhibition With Nivolumab for the Treatment of Patients With Acute Myeloid Leukemia in Remission at High Risk for Relapse
In Brief
A Phase 2 clinical trial evaluating Laboratory Biomarker Analysis and Nivolumab for Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome and 3 related conditions. Completed, enrolled 15 participants across 1 site.
Detailed Summary
This phase II trial studies how well nivolumab works in treating patients with acute myeloid leukemia that has decreased or disappeared but may still be in the body (remission), and is at high risk for returning (relapse). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Study Details
Timeline
Interventions
Correlative studies
Given IV